Imiquimod


Thông tin thuốc gốc
Chỉ định và Liều dùng
Topical/Cutaneous
Actinic keratoses
Adult: For the treatment of clinically typical, nonhyperkeratotic, nonhypertrophic, visible or palpable cases: As 2.5% or 3.75% cream: Apply thinly onto the entire face or balding scalp once daily before bedtime for 2 weeks; after a 2-week treatment-free interval, repeat a 2nd 2-week treatment course. Assess response 8 weeks after the 2nd course. Max: 2 sachets daily or 2 full pump actuations daily. Rest periods may be taken if local skin reactions occur, but treatment period must not be extended due to missed doses or rest periods. Therapy must be continued for the full treatment course even if all actinic keratoses appear to be gone. As 5% cream: Apply onto the face or scalp 3 times each week before bedtime for 4 weeks; after a 4-week treatment-free interval, assess response then repeat another 4-week treatment course if any lesions persist. Alternatively, apply onto the face or scalp 2 times each week for 16 weeks. Max: 1 sachet at each application. Rest periods may be taken if local skin reactions occur, but the treatment period must not be extended beyond 4 weeks or 16 weeks due to missed doses or rest periods. All doses must be left on the skin for approx 8 hours, then washed with mild soap and water. Dosage and treatment recommendations may vary among individual products or between countries (refer to specific product or local guidelines).

Topical/Cutaneous
Superficial basal cell carcinoma
Adult: For the treatment of biopsy-confirmed cases with a max tumour diameter of 2 cm located on the neck, trunk (except anogenital skin), or extremities (except hands and feet) when surgical methods are less appropriate and patient follow-up can be assured: As 5% cream: Apply sufficient amount to cover the lesion and 1 cm beyond it 5 times each week (on consecutive days) before bedtime; leave on skin for approx 8 hours, then wash with mild soap and water. Treatment duration: 6 weeks. Assess response 12 weeks after treatment completion.

Topical/Cutaneous
Genital warts, Perianal warts
Adult: As 3.75% cream: Apply thinly onto the affected area(s) once daily before bedtime; leave on the skin for approx 8 hours, then wash with mild soap and water. Continue treatment until total clearance or for a Max duration of 8 weeks. As 5% cream: Apply thinly 3 times each week (on alternate days) before bedtime; leave on the skin for 6-10 hours, then wash with mild soap and water. Continue treatment until total clearance or for a Max duration of 16 weeks. Dosage and treatment recommendations may vary among individual products or between countries (refer to specific product or local guidelines).
Thận trọng
Patient with pre-existing autoimmune disorders, inherent sensitivity to sunlight or potential for considerable sun exposure (e.g. occupational reasons); reduced haematologic reserve. Immunocompromised patients, including organ transplant patients. Uncircumcised males. Not indicated for urethral, cervical, rectal, intravaginal, or intra-anal HPV disease. Not recommended to be used until the skin has healed from any previous sunburn, drug or surgical treatment. Not intended for oral, nasal, or ophthalmic use. Pregnancy and lactation.
Tác dụng không mong muốn
Significant: Intense local inflammatory reactions (e.g. skin weeping or erosion), photosensitivity, severe vulvar swelling which may lead to urinary retention; flu-like symptoms (e.g. chills, fever, fatigue, arthralgia, malaise); may exacerbate autoimmune disorders or inflammatory skin conditions (including graft-versus-host-disease).
Blood and lymphatic system disorders: Lymphadenopathy.
Cardiac disorders: Chest pain.
Gastrointestinal disorders: Nausea, vomiting, diarrhoea.
General disorders and administration site conditions: Application site reactions (e.g. dryness, pruritus, pain, irritation, burning sensation, rash, erythema, oedema, paraesthesia, discharge, scabbing, exfoliation, ulceration).
Infections and infestations: Fungal infection, herpes simplex.
Investigations: Increased blood glucose.
Metabolism and nutrition disorders: Anorexia.
Musculoskeletal and connective tissue disorders: Myalgia, back pain.
Neoplasms benign, malignant and unspecified: Squamous cell carcinoma.
Nervous system disorders: Headache, dizziness.
Psychiatric disorders: Insomnia.
Reproductive system and breast disorders: Bacterial vaginosis.
Respiratory, thoracic and mediastinal disorders: URTI, sinusitis.
Skin and subcutaneous tissue disorders: Skin hypopigmentation or hyperpigmentation, dermatitis, erythema multiforme.
Thông tin tư vấn bệnh nhân
Avoid contact with eyes, lips, nostrils and broken skin. Avoid or minimise exposure to sunlight, UV lights, and tanning beds; use protective clothing during therapy. Avoid the use of excessive amounts of cream or occlusive dressing. Avoid sexual contact while the cream is on the skin as it may weaken condoms and diaphragms (when used for external genital or perianal warts).
Chỉ số theo dõi
Establish a histological basis for superficial basal cell carcinoma prior to therapy. Periodically assess response to treatment, particularly for a reduction in lesion size. Monitor for local skin reactions and signs and symptoms of hypersensitivity.
Tác dụng
Description:
Mechanism of Action: Imiquimod is an immune response modifier and a Toll-like receptor 7 agonist that activates immune cells. Its exact mechanism of action has not been determined; however, it may induce the release of interferon-α (IFN-α) and other cytokines and enhance cell-mediated cytolytic antiviral activity.
Pharmacokinetics:
Absorption: Minimal systemic absorption. Time to peak plasma concentration: 9-12 hours.
Excretion: Via urine (<3% as unchanged drug and metabolites).
Đặc tính

Chemical Structure Image
Imiquimod

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 57469, Imiquimod. https://pubchem.ncbi.nlm.nih.gov/compound/Imiquimod. Accessed Nov. 23, 2023.

Bảo quản
Store below 25°C. Do not freeze. Keep the cream in pump bottle upright.
Phân loại MIMS
Các sản phẩm da liễu khác
Phân loại ATC
D06BB10 - imiquimod ; Belongs to the class of topical antivirals used in the treatment of dermatological diseases.
Tài liệu tham khảo
Aldara 5% Cream (Mylan Products Ltd). MHRA. https://products.mhra.gov.uk. Accessed 11/10/2023.

Aldara Cream (Bausch Health US LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 27/06/2023.

Aldara Cream 5% w/w (iNova Pharmaceuticals [Singapore] Pte Ltd [Incorporated in Singapore] Malaysia Branch). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 27/06/2023.

Anon. Imiquimod. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 27/06/2023.

Anon. Imiquimod. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 27/06/2023.

Buckingham R (ed). Imiquimod. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 27/06/2023.

Joint Formulary Committee. Imiquimod. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 27/06/2023.

Orion Laboratories (NZ) Ltd. Imiquimod Cream 5% w/w Topical Cream data sheet 22 September 2017. Medsafe. http://www.medsafe.govt.nz. Accessed 29/06/2023.

Zyclara 3.75% Cream (Mylan Products Ltd). MHRA. https://products.mhra.gov.uk. Accessed 27/06/2023.

Zyclara Cream (Bausch Health US, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 11/10/2023.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Imiquimod từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2024 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
  • Aldara
  • Imiquad
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Đăng nhập
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Đăng nhập